Hanmi Pharmaceutical Surges 10,000 Won to 379,000 Won... Obesity Business Expands from GLP-1 New Drug 'Efpeglenatide' to Health Supplement 'Epislim'
Hanmi Pharmaceutical showed strength on the 29th, recording 379,000 won, up 10,000 won in early trading. Market attention is focused on Hanmi Pharmaceutical's business moves in the obesity and metabolic disease sectors. Following the development of an obesity treatment, the company is expanding its

Hanmi Pharmaceutical showed strength on the 29th, recording 379,000 won, up 10,000 won in early trading.
Market attention is focused on Hanmi Pharmaceutical's business moves in the obesity and metabolic disease sectors. Following the development of an obesity treatment, the company is expanding its product lineup into the health functional food market, broadening its business scope.
■ Launch of Health Functional Food 'Epislim' Following GLP-1 New Drug Approval
After obtaining product approval for 'efpeglenatide,' introduced as Korea's first GLP-1 obesity new drug, Hanmi Pharmaceutical has newly unveiled the health functional food brand 'epislim,' which takes into account both weight management and physical health.
Epislim, unveiled on the 27th, focuses on the physical changes that consumers are interested in during the weight loss process. Hanmi Pharmaceutical blended common supplementary ingredients so that consumers can also pay attention to gastrointestinal health while managing their weight.
This expansion of the product lineup also draws attention in that pharmaceutical companies' approaches to the obesity management market are becoming more diverse.
■ Healthcare Business Expansion... Sales Performance Must Prove Results
Hanmi Pharmaceutical plans to broaden the scope of its healthcare business, including health functional foods, based on the research and development (R&D) experience it has accumulated in the obesity and metabolic disease fields.
The market may take interest in the fact that Hanmi Pharmaceutical's obesity-related business is being diversified into new drug development and health functional foods. However, whether the launch of new products will actually lead to increased revenue or improved profitability must be confirmed through future sales performance.
[This article is intended to provide information for investment reference and does not recommend the purchase or sale of specific stocks. Content may vary depending on market conditions. Investment decisions and the responsibility for them rest with the investor. The functionality and effects of each product may vary by individual. AI provided some assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



